Treats hypertension. ANDA 202230, held by Macleods Pharmaceuticals. Losartan Potassium.
As of Nov 21, 2026, ANDA 202230 (Losartan Potassium), held by Macleods Pharmaceuticals, was first approved by FDA on May 30, 2012, with 7 approved supplements and 0 published complete response letters.
Losartan potassium tablets, USP are an angiotensin II receptor blocker (ARB) indicated for:
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 30, 2012 | Original application | Approved | None posted |
| Losartan Potassium25MG · tablet;oral | Losartan Potassium | Rx |
| Losartan Potassium50MG · tablet;oral | Losartan Potassium | Rx |
| Losartan Potassium100MG · tablet;oral | Losartan Potassium | Rx |
| Jun 7, 2023 | Supplement 20Labeling · Standard review | Approved | None posted |
| Feb 28, 2023 | Supplement 19Labeling · Standard review | Approved | None posted |
| May 21, 2019 | Supplement 10Labeling · Standard review | Approved | None posted |
| Jun 9, 2016 | Supplement 6Labeling · Standard review | Approved | None posted |
| Nov 12, 2015 | Supplement 5Labeling · Standard review | Approved | None posted |
| Nov 4, 2014 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jan 28, 2013 | Supplement 1Labeling · Standard review | Approved | None posted |
| May 30, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters